KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Net Cash Flow (2016 - 2025)

Pfizer (PFE) has disclosed Net Cash Flow for 17 consecutive years, with -$202.0 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow changed N/A to -$202.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.0 million through Dec 2025, up 101.41% year-over-year, with the annual reading at $49.0 million for FY2025, 102.81% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$202.0 million at Pfizer, up from -$304.0 million in the prior quarter.
  • The five-year high for Net Cash Flow was $1.8 billion in Q2 2023, with the low at -$2.1 billion in Q1 2024.
  • Average Net Cash Flow over 5 years is -$41.8 million, with a median of $173.0 million recorded in 2025.
  • The sharpest move saw Net Cash Flow surged 3633.33% in 2022, then tumbled 405.84% in 2024.
  • Over 5 years, Net Cash Flow stood at $241.0 million in 2021, then crashed by 310.37% to -$507.0 million in 2022, then skyrocketed by 38.07% to -$314.0 million in 2023, then crashed by 450.32% to -$1.7 billion in 2024, then soared by 88.31% to -$202.0 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$202.0 million, -$304.0 million, and $173.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.